Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | +6.54% | +24.77% | -17.86% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.86% | 162M | |
+18.50% | 123B | |
+15.34% | 107B | |
-4.05% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-12.48% | 16.23B | |
+3.93% | 13.43B | |
+26.26% | 11.32B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating